Trichosporon beigelii: A life-threatening pathogen in immunocompromised hosts

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 745-749

  Erer, B ^a   Galimberti, M ^a   Lucarelli, G ^a   Giardini, C ^a   Polchi, P ^a   Baronciani, D ^a   Gaziev, D ^a   Angelucci, E ^a   Izzi, G ^b  

^a Div Ematologia Ctro Trapianti M   (Italy)

^b NONE

Author keywords

Bone marrow transplantation; Immunosuppression; Tricosporon beigelii

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHILD; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SCHOOL CHILD; TRICHOSPORON BEIGELII;

EID: 0034027252     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702231     Document Type: Article

References (37)

1. Rippon JW, Superficial infections. In: Rippon JW (ed). Medical Mycology, 2nd edn. WB Saunders: Philadelphia, 1979, pp 148-151.
2. Hoy J, Hsu KC, Rolston K et al. Trichosporon beigelii infection: a review. Rev Infect Dis 1986; 8: 959-967.
3. Yoss BS, Sautter RL, Brenker HJ. Trichosporon beigelii, a new neonatal pathogen. Am J Perinatol 1997; 14: 113-117.
4. Keay S, Denning DW, Stevens DA. Endocarditis due to Trichosporon beigelii: in vitro susceptibility of isolates and review. Rev Infect Dis 1991: 13: 383-386.
5. Brahn E, Leonard PA. Trichosporon cutaneum endocarditis: a sequela of intravenous drug-abuse. Am J Clin Path 1982; 78: 792-794.
6. Ashpole RD, Jacobson K, King AT, Holmes AE. Cystoperitoneal shunt infection with Trichosporon beigelii. Br J Neurosurg 1991; 5: 515-517.
7. Muramatsu H, Kume H, Hojo M et al. A case of Trichosporon beigelii peritonitis in CAPD. Kansenshogaku Zasshi 1992; 66: 1129-1132.
8. Mathews MS, Prabhakar S. Chronic meningitis caused by Trichosporon beigelii in India. Mycoses 1995; 38: 125-126.
9. Bottari M, D'Amore F, Buda CA et al. Stenosing esophagitis caused by Trichosporon beigelii: presentation of a rare case. G Chir 1997; 18: 344-347.
10. Sheikh HA, Mahgoub S, Badi K. Postoperative endophthalmitis due to Trichosporon cutaneum. Br J Ophthalmol 1974; 58: 591-594.
11. Gardella S, Nomdedeu B, Bombi JA et al. Fatal fungemia with arthritic involvement caused by Trichosporon beigelii in a bone marrow transplant recipient. J Infect Dis 1985; 151: 566.
12. Patel SA, Borges MC, Batt MD, Rosenblate JH. Trichosporon cholangitis associated with hyperbilirubinemia and findings suggesting primary sclerosing cholangitis on endoscopic retrograde cholangiopancreatography. Am J Gastroenterol 1990; 85: 84-87.
13. Korinek JK, Guarda LA, Bolivar R, Stroehlein JR. Trichosporon hepatitis. Gastroenterology 1983; 85: 732-734.
14. Nishiura Y, Nakagawa-Yoshida K, Suga M et al. Assignment and serotyping of Trichosporon species: the causative agents of summer-type hypersensitivity pneumonitis. J Med Vet Mycol 1997; 35: 45-52.
15. McBride ME, Kalter DC, Wolf JE Jr. Antifungal susceptibility testing of Trichosporon beigelii to imidazole compounds. Can J Microbiol 1988; 34: 850-854.
16. Walsh TJ, Melcher GP, Rinaldi MG et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1612-1622.
17. Nasu K, Akuzuki S, Yoshiyama K et al. Disseminated Trichosporon infection. A case report and immunohistochemical study. Arch Pathol Lab Med 1994; 118: 191-194.
18. Muranaka H, Suga M, Nakagawa K et al. Effects of granulocyte and granuloyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis. Infect Immun 1997; 65: 3422-3429.
19. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med 1990; 322: 417-421.
20. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
21. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
22. Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3-11.
23. O'Donnell MR, Schmidt GM, Tegtmeier BR et al. Prediction of systemic fungal infection in allogeneic marrow recipients. Impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827-834.
24. Jesse L, Goodman MD, Drew J et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
25. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22 (Suppl. 2): S112-S118.
26. Watson KC, Kallichurum S. Brain abscess due to Trichosporon cutaneum. J Med Microbiol 1970; 3: 191-193.
27. Martinez LJ, Mana J, Niubo R et al. Long-term survival of a patient with prosthetic valve endocarditis due to Trichosporon beigelii. Eur J Clin Microbiol Infect Dis 1991; 10: 756-758.
28. Reinhart HH, Urbanski DM, Harrington SD, Sobel JD. Prosthetic valve endocarditis caused by Trichosporon beigelii. Am J Med 1988; 84: 355-358.
29. McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21: 681-685.
30. McManus EJ, Bozdech MJ, Jones JM. Role of the latex agglutination test for cryptococcal antigen in diagnosing disseminated infections with Trichosporon beigelii. J Infect Dis 1985; 151: 1167-1169.
31. Melcher GP, Reed KD, Rinaldi MG et al. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol 1991; 29: 192-196.
32. Anaissie E, Gokaslan A, Hachem R et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy of murine infection, and review. Clin Infect Dis 1992; 15: 781-787.
33. Perparim K, Nagai H, Hashimoto A et al. In vitro susceptibility of Trichosporon beigelii to antifungal agents. J Chemother 1996; 8: 445-448.
34. Espinel Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1988; 36: 198-202.
35. Sutton DA, Sanche SE, Revankar SG et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345.
36. Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents against clinical isolates of filamentous fungi. Med Mycol 1998; 36: 433-436.
37. Wildfeuer A, Seidl HP, Paole I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998; 41: 309-319.